Pharmafile Logo
Pharmafocus logo
Advanced Search

American pharmacy adds 35 products to list of excluded drugs

August 4, 2016
Sales and Marketing Drug pricing, cvs health, excluded drugs, hyperinflationary

American pharmacy chain CVS Health has added 35 products to its list of excluded drugs and will not cover certain …

News
roche_south

Roche cuts ties with Inovio in hepatitis B development

August 3, 2016
Research and Development Inovio, Roche, hepatitis B

Inovio Pharmaceuticals has announced that it will independently continue development of hepatitis B immunotherapy, INO-1800, after Swiss drugmaker Roche issued …

News
biogen_austria_238

Takeover rumours send Biogen’s stock soaring

August 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover

Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …

News
celgene_1_02

Celgene’s Otezla approved for NHS use

August 3, 2016
Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast

NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of …

News
teva_copy

Teva completes $40 billion acquisition of Actavis Generics

August 3, 2016
Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics

Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …

News
merck_incweb

MSD scores EU approval for Keytruda in lung cancer

August 3, 2016
Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …

News
novartis_building

Breakthrough therapy designation for Novartis in advanced breast cancer treatment

August 3, 2016
Research and Development, Sales and Marketing Breakthrough Therapy Designation, FDA, LEE011, Novartis, ribociclib

Novartis has announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to LEE011 (ribociclib) …

News
shire_image

Shire Q2 results outpace forecasts with 56% revenue growth

August 2, 2016
Research and Development, Sales and Marketing Baxalta, Shire, financial report

Shire has announced its fiscal results for Q2 2016, reporting a strong quarter with a 56% growth in total revenues …

News
pfizer_reflection

Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations

August 2, 2016
Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results

Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …

News

Landmark UK ruling as judge rules PrEP can be funded on NHS

August 2, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Judge, NHS, PrEP, UK, available, ruling

A London high court judge has ruled in favour of a challenge brought by the National Aids Trust to allow …

News

Joint Article on Hydrogen Peroxide Efficacy Published in Letters in Applied Microbiology

August 2, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wickham laboratories

Wickham Laboratories Ltd is pleased to announce the publication of a joint study with Bioquell on the efficacy of disinfection …

News
Press release
eisa0002

Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England

August 2, 2016
Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer

Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …

News
biogen_austria_238

Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III

August 2, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …

News
pfizer_credit_flickr__ceiling

Pfizer expands gene therapy operations with acquisition of Bamboo Therapeutics

August 2, 2016
Manufacturing and Production, Research and Development Pfizer, acquisition, bamboo therapeutics, gene therapy

Pfizer has announced that it has acquired gene therapy biotech Bamboo Therapeutics for an initial $150 million, with potential milestone …

News
takeda_tokyo_hq

Phase III success for Takeda in lymphoma drug

August 1, 2016
Manufacturing and Production, Research and Development Adcetris, Seattle Genetics, Takeda, lymphoma

Takeda Oncology and Seattle Generic have announced new Phase III data for trial drug, Adcetris (brentuximab vedotin), in patients with …

News

FDA approves Shire’s haemophilia A treatment system

August 1, 2016
Manufacturing and Production, Research and Development FDA, Shire, adynovate, baxject, haemophilia

Shire has announced that the Food and Drug Administration (FDA) has approved the baxject III reconstitution system for adynovate [antihemophilic …

News
brexit

The impact of Brexit on the pharmaceutical industry: some preliminary considerations

August 1, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing brexit

The outcome of the popular vote cast on 23 June 2016 will be remembered as the start of a new …

Feature

Sartorius doubles production capacity in UK with new facility

August 1, 2016
Manufacturing and Production, Sales and Marketing Princess Anne, Sartorius, UK, expansion

Pharmaceutical and laboratory equipment provider Sartorius has expanded operations at its Stonehouse site in Gloucestershire with a new plant, doubling …

News
merck_and_co

European Commission approves Zepatier for chronic hepatitis C infection

August 1, 2016
Research and Development, Sales and Marketing

MSD, known as Merck in the US and Canada, has announced that the European Commission has approved Zepatier (elbasvir/grazoprevir) with …

News

Surprise for Seres as shares sent tumbling by Phase II failure

August 1, 2016
Research and Development, Sales and Marketing FDA, clostrodium difficile, seres therapeutics

Seres Therapeutics has presented interim results from an ongoing Phase II trial which has sent company stock spiralling downward, as …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026